Skip to main content

Advertisement

SpringerLink
Log in

Current Approaches in Antifungal Prophylaxis in High Risk Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients

  • Published:
Mycopathologia Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Invasive fungal infections (IFIs) pose the most serious infectious risk to patients with hematologic malignancies and in those undergoing hematopoietic stem cell transplantation (HSCT). Invasive candidiasis has an incidence of 8–18% and a mortality of 30–40% in various reports. Invasive aspergillosis has an incidence of 4–15% and an even higher mortality of 60–85% cited in the published literature. IFIs have remained difficult to diagnose in a timely way in neutropenic and immunocompromised patients. A timely diagnosis is essential in promptly initiating antifungal therapy in order to optimize clinical outcomes. Thus, antifungal prophylaxis has an enormous appeal to minimize the threat from IFIs. In this article, the epidemiology and risk factors for IFIs as well as evidence from antifungal prophylaxis clinical trials in certain patient groups with hematologic malignancies are reviewed. Antifungal prophylaxis has been shown to be effective in certain settings. However, concerns about shifts in fungal epidemiology, emergence of resistance, drug toxicities, and drug interactions must be considered in deciding how and in whom to use antifungal prophylaxis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wingard JR, Leather HL. A new era of antifungal therapy. Biol Blood Marrow Transplant. 2004;10:73–90. doi:10.1016/j.bbmt.2003.09.014.

    Article  CAS  PubMed  Google Scholar 

  2. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2003;100:4358–66. doi:10.1182/blood-2002-05-1496.

    Article  CAS  Google Scholar 

  3. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted risk-based anti-fungal strategy in neutropenic patients. Br J Haematol. 2000;110:273–84. doi:10.1046/j.1365-2141.2000.02014.x.

    Article  CAS  PubMed  Google Scholar 

  4. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. Clin Microbiol Rev. 1997;10:444–65.

    CAS  PubMed  Google Scholar 

  5. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373–9. doi:10.1086/509917.

    Article  PubMed  Google Scholar 

  6. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42:1417–27. doi:10.1086/503427.

    Article  CAS  PubMed  Google Scholar 

  7. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1 → 3)-Beta-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2005;43:5957–62. doi:10.1128/JCM.43.12.5957-5962.2005.

    Article  CAS  PubMed  Google Scholar 

  8. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the anti-leukemic regimen. Clin Infect Dis. 1995;21:361–9.

    CAS  PubMed  Google Scholar 

  9. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol. 1990;17:10–3.

    CAS  PubMed  Google Scholar 

  10. Tortorano AM, Kibbler C, Perman J, Bernhardt H, Klingspor L, Grillot R. Candidemia in Europe: epidemiology and resistance. Int J Antimicrob Agents. 2006;27:359–66. doi:10.1016/j.ijantimicag.2006.01.002.

    Article  CAS  PubMed  Google Scholar 

  11. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;326:1274–7.

    Article  Google Scholar 

  12. Pasqualotto AC, Rosa DD, Medeiros LR, Severo LC. Candidemia and cancer: patients are not all the same. BMC Infect Dis. 2006;6:1–7. doi:10.1186/1471-2334-6-50.

    Article  Google Scholar 

  13. Gerson SL, Talbot GH, Lusk E, Hurwitz S, Strom BL, Cassileth P. Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis. J Clin Oncol. 1985;3:1109–16.

    CAS  PubMed  Google Scholar 

  14. Talbot GH, Weiner MH, Gerson SL, Provencher M, Hurwitz S. Serodiagnosis of invasive aspergillosis in patients with hematologic malignancy: validation of the Aspergillus fumigatus antigen radioimmunoassay. J Infect Dis. 1987;155:12–27.

    CAS  PubMed  Google Scholar 

  15. Winston D, Chandrasekar P, Lazarus H, Goodman J, Silber J, Horowitz H, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind nulticenter trial. Ann Intern Med. 1993;118:495–503.

    CAS  PubMed  Google Scholar 

  16. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis. 1999;28:331–40. doi:10.1086/515128.

    Article  CAS  PubMed  Google Scholar 

  17. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068–75.

    PubMed  Google Scholar 

  18. Borlenghi E, Cattaneo C, Capucci M, Pan A, Quaresmini G, Franco F, et al. Usefulness of the MSG/IFICG/EORTC diagnostic criteria for invasive pulmonary aspergillosis in the clinical management of patients with acute leukemia developing pulmonary infiltrates. Ann Hematol. 2007;86:205–10. doi:10.1007/s00277-006-0204-3.

    Article  PubMed  Google Scholar 

  19. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis—has the principle been proven? N Engl J Med. 2007;356:409–11. doi:10.1056/NEJMe068266.

    Article  PubMed  Google Scholar 

  20. Cornely OA, Maerten J, Winston D, Perfect J, Ullman A, Walsh T, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–59. doi:10.1056/NEJMoa061094.

    Article  CAS  PubMed  Google Scholar 

  21. Jantunen E, Ruutu P, Niskanen L, Vulin L, Parkkali T, Koukila-Kahkola P, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT patients. Bone Marrow Transplant. 1997;19:801–8. doi:10.1038/sj.bmt.1700737.

    Article  CAS  PubMed  Google Scholar 

  22. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984;100:345–51.

    CAS  PubMed  Google Scholar 

  23. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospection, randomized, double-blind study. J Infect Dis. 1995;171:1545–52.

    CAS  PubMed  Google Scholar 

  24. Marr K, Seidel K, Slavin M, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96:2055–61.

    CAS  PubMed  Google Scholar 

  25. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–51.

    CAS  PubMed  Google Scholar 

  26. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459–66.

    Article  CAS  PubMed  Google Scholar 

  27. Ribaud P, Chastang C, Latge JP, Buffroy-Lafitte L, Parquet N, Devergie A, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis. 1999;28:322–30. doi:10.1086/515116.

    Article  CAS  PubMed  Google Scholar 

  28. Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine. 1993;72:78–9. doi:10.1097/00005792-199303000-00002.

    Article  CAS  PubMed  Google Scholar 

  29. Iwen PC, Reed EC, Armitage JO, Bierman PJ, Kessinger A, Bose JM, et al. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol. 1993;14:131–9.

    Article  CAS  PubMed  Google Scholar 

  30. Maertens JA, Verhaegen J, Lagrou K, van Eldere J, Boogaerts M, et al. Screening for circulating galactomannan as a non-invasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604–10. doi:10.1182/blood.V97.6.1604.

    Article  CAS  PubMed  Google Scholar 

  31. Sherertz RJ, Belani A, Kramer BS, Elfenbein GJ, Weiner RS, Sullivan ML, et al. Impact of air filtration on nosocomial aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med. 1987;83:709–18. doi:10.1016/0002-9343(87)90902-8.

    Article  CAS  PubMed  Google Scholar 

  32. Grow WB, Moreb JS, Roque D, Manion K, Leather H, Reddy V, et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant. 2002;29:15–9. doi:10.1038/sj.bmt.1703332.

    Article  CAS  PubMed  Google Scholar 

  33. Gil L, Styczynski J, Komarnicki M. Infectious complications in 314 patients after high-dose therapy and autologous stem cell transplantation: risk factors analysis and outcome. Infection. 2007;35:421–7. doi:10.1007/s15010-007-6350-2.

    Article  CAS  PubMed  Google Scholar 

  34. Gil L, Kozlowska-Skrzypczak M, Mol A, Poplawski D, Styczynski J, Komarnicki M. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant. 2008; Sep 15 e-pub.

  35. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–17. doi:10.1086/339202.

    Article  PubMed  Google Scholar 

  36. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B-or triazole-pre-exposed cancer patients with positive cultures for aspergillus. Diagn Miccrobiol Infect Dis. 2005;52:15–20. doi:10.1016/j.diagmicrobio.2005.01.001.

    Article  CAS  Google Scholar 

  37. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case–control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–60. doi:10.1086/428780.

    Article  PubMed  Google Scholar 

  38. Park BJ, Kontoyiannis DP, Pappas PG, et al. Comparison of zygomycosis and fusariosis to invasive aspergillosis (IA) among transplant recipients reporting to TRANSNET. In: Program and Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30–November 2, 2004, Washington, DC, Abstract M-666.

  39. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2006;108:2928–36. doi:10.1182/blood-2006-03-008706.

    Article  CAS  PubMed  Google Scholar 

  40. Chao N, Emerson SG, Weinberg K. Stem cell transplantation (cord blood transplants). Hematology Am Soc Hematol Educ Program. 2004;354–71. doi:10.1182/asheducation-2004.1.354.

  41. Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner KA, Wright KA, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis. 1992;165:891–7.

    CAS  PubMed  Google Scholar 

  42. Cordonnier C, Mohty M, Faucher C, Pautas C, Robin M, Vey N, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME study. Int J Antimicrob Agents. 2008;31:135–41. doi:10.1016/j.ijantimicag.2007.10.001.

    Article  CAS  PubMed  Google Scholar 

  43. El-Cheik J, Faucher C, Furst S, Duran S, Berger P, Vey N, et al. High dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplant. Bone Marrow Transplant. 2007;39:301–6. doi:10.1038/sj.bmt.1705592.

    Article  CAS  Google Scholar 

  44. Jansen J, Akard LP, Wach MF, Thompson JM, Dugan MJ, Leslie JK, et al. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation. Mycoses. 2006;49:397–404. doi:10.1111/j.1439-0507.2006.01264.x.

    Article  PubMed  Google Scholar 

  45. Marr KA, Laverdiere M, Gugel M, Leisenring W. Antifungal therapy decreases sensitivity of Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40:1762–9. doi:10.1086/429921.

    Article  CAS  PubMed  Google Scholar 

  46. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood. 1999;93:3651–6.

    Google Scholar 

  47. Griese M, Schams A, Lohmeier KP. Amphotericin B and pulmonary surfactant. Eur J Med Res. 1998;3:383–6.

    CAS  PubMed  Google Scholar 

  48. Ruijgrok EJ, Vultro AG, Van Etten EW. Efficacy of aerosolized amphotericin B deosycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother. 2001;48:89–95. doi:10.1093/jac/48.1.89.

    Article  CAS  PubMed  Google Scholar 

  49. Alexander BD, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, Perfect JR. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2006;8:13–20. doi:10.1111/j.1399-3062.2006.00125.x.

    Article  CAS  PubMed  Google Scholar 

  50. Rijnders BJ, Cornelissen JS, Slobbe L, Becker MJ, Duorduijn JK, Hop WCJ, et al. Aerosolized liposomal Amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46:1401–8. doi:10.1086/586739.

    Article  CAS  PubMed  Google Scholar 

  51. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962–8. doi:10.1056/NEJM199804023381405.

    Article  CAS  PubMed  Google Scholar 

  52. Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Arai C, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized controlled trials. Cancer. 2000;89:1611–25. doi:10.1002/1097-0142(20001001)89:7<1611::AID-CNCR27>3.0.CO;2-B.

    Article  CAS  PubMed  Google Scholar 

  53. MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med. 2002;112:369–79. doi:10.1016/S0002-9343(01)01127-5.

    Article  CAS  PubMed  Google Scholar 

  54. Kern W, Behre G, Rudolf T, Kerkhoff A, Grote-Metke A, Eimermacher H, et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer. 1998;83:291–301. doi:10.1002/(SICI)1097-0142(19980715)83:2<291::AID-CNCR13>3.3.CO;2-C.

    Article  CAS  PubMed  Google Scholar 

  55. Recommendations of the Center for Disease Control and Prevention, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2000;6:659–734.

    Google Scholar 

  56. Glassmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3597 patients. J Clin Oncol. 2003;21:4615–26. doi:10.1200/JCO.2003.04.052.

    Article  CAS  Google Scholar 

  57. Winston DJ, Maziarz RT, Chandrasekar Ph, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med. 2003;138:705–13.

    CAS  PubMed  Google Scholar 

  58. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527–33. doi:10.1182/blood-2003-08-2644.

    Article  CAS  PubMed  Google Scholar 

  59. Oren I, Rowe JM, Sprecher H, Tamir A, Benyamini N, Akria L, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2006;38:127–34. doi:10.1038/sj.bmt.1705418.

    Article  CAS  PubMed  Google Scholar 

  60. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005;131:22–8.

    Google Scholar 

  61. De Beule KL. Itraconazole: pharmacology, clinical experience, and future development. Int J Antimicrob Agents Chemother. 1996;6:175–81. doi:10.1016/0924-8579(95)00043-7.

    Article  Google Scholar 

  62. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother. 2005;56:i33–8. doi:10.1093/jac/dki222.

    Article  CAS  PubMed  Google Scholar 

  63. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad spectrum triazole antifungal. Lancet Infect Dis. 2005;5:775–85. doi:10.1016/S1473-3099(05)70297-8.

    Article  CAS  PubMed  Google Scholar 

  64. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CG, Lipton JH, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407–16. doi:10.1086/422312.

    Article  PubMed  Google Scholar 

  65. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichmer L, Cortes J, O’brien S, et al. Open label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50:143–7. doi:10.1128/AAC.50.1.143-147.2006.

    Article  CAS  PubMed  Google Scholar 

  66. Ullman AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft versus host disease. N Engl J Med. 2007;356:335–47. doi:10.1056/NEJMoa061098.

    Article  Google Scholar 

  67. Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother. 2000;34:1032–43. doi:10.1345/aph.19237.

    Article  CAS  PubMed  Google Scholar 

  68. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID, et al. Results of fluconazole (FLU) vs voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood. 2007;110:55a. Abstract #163.

    Google Scholar 

  69. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, et al. Voriconazole therapeutic drug monitoring in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005;35:509–13. doi:10.1038/sj.bmt.1704828.

    Article  CAS  PubMed  Google Scholar 

  70. Pascual A, Nieth V, Calandra T, Bille J, Bolay S, Docosterd LA, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemo. 2007;51:137–43. doi:10.1128/AAC.00957-06.

    Article  CAS  Google Scholar 

  71. Walsh TJ, Raad I, Patterson TF, Chandrashekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2–12. doi:10.1086/508774.

    Article  CAS  PubMed  Google Scholar 

  72. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27:1627–36. doi:10.1592/phco.27.12.1627.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, College of Medicine, Bone Marrow Transplant Program, University of Florida, 1600 SW Archer Road, P.O. Box 100277, Gainesville, FL, 32610, USA

    Baldeep Wirk & John R. Wingard

Authors
  1. Baldeep Wirk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John R. Wingard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Baldeep Wirk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wirk, B., Wingard, J.R. Current Approaches in Antifungal Prophylaxis in High Risk Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients. Mycopathologia 168, 299–311 (2009). https://doi.org/10.1007/s11046-009-9188-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11046-009-9188-6

Keywords

Search

Navigation